Page URL: https://www.bionews.org.uk/page_92138

Genetic test helps predict risk of death from prostate cancer

31 January 2010
Appeared in BioNews 543

A combination of three genetic alterations that dramatically reduce chances of surviving prostate cancer have been identified by researchers at the UK's Institute of Cancer Research (ICR). It is hoped that this finding could lead to the development of a genetic test to help doctors decide how aggressively to treat tumours.

The research team, led by Dr Alison Reid, published its work in this month's online edition of the British Journal of Cancer. The report describes how the group screened prostate tumour samples for alterations in three genes - PTEN (a known tumour suppressor gene), ERG and ETV1. They found that loss of the PTEN gene and lack of rearrangements in the ERG and ETV1 genes led to a higher risk of dying from cancer. Only 13.7 per cent of the patients with this combination of genetic alterations were alive after 11 years, compared with 85 per cent of those with the normal form of the genes.

In an ICR press release, Dr Reid suggested that 'men diagnosed with prostate cancer could be tested for all three genetic alterations, and this information could be used to help determine how aggressively they should be treated'.

Prostate cancer is the most common cancer in men world-wide. It affects more than 35,000 men in Britain each year and only two-thirds survive the disease. Patients typically fall into two groups - those with an aggressive form of the disease who need immediate treatment, and those with slow growing tumours who may not even require treatment. Professor Colin Cooper, head of the Everyman Male Cancer Campaign and a co-author on the study, emphasised that 'there is an urgent need to find biological markers like these that will help us distinguish between the two groups of patients'.

Helen Rippon, head of research at the Prostate Cancer Charity, cautioned that the new test to distinguish between high- and low-risk patients would not necessarily prolong the lives of carriers of the high-risk genetic alterations. She explained that 'the next stage will be to carry out a 'prospective' clinical trial using the new test to identify men with a poor prognosis and select them for aggressive treatment'.

If clinical trials are successful the new test could also benefit the patients with a low risk of dying from the disease. Two studies published in the New England Journal of Medicine in March 2009 found that current tests used to screen for prostate cancer frequently lead to risky and unnecessary treatment in low-risk patients.
SOURCES & REFERENCES
Genes 'radically reduce chances of surviving prostate cancer'
Daily Telegraph |  27 January 2010
Genetic factors key to prostate cancer death risk
Reuters |  27 January 2010
Genetic test gives patients their chances of surviving prostate cancer
Daily Mail |  27 January 2010
Test 'identifies prostate risk'
The Press Association |  27 January 2010
RELATED ARTICLES FROM THE BIONEWS ARCHIVE
2 July 2012 - by Dr Zara Mahmoud 
A test which screens for levels of gene expression may help reduce the number of patients with benign thyroid cancer who are put forward for unnecessary surgery...
14 February 2011 - by Victoria Kay 
A genetic screening test could help doctors to identify men with the most aggressive types of prostate cancer, UK scientists believe. The test could save men with milder forms of the disease from unnecessary surgery and its potentially serious side effects...
14 February 2011 - by Dr Lucy Freem 
US researchers have sequenced the genomes of several prostate tumours providing new information that may help doctors to identify aggressive forms of the cancer and prioritise treatment...
29 March 2010 - by Dr Vivienne Raper 
Infertile men may be more likely to develop aggressive prostate cancer, according to US researchers. But The Prostate Cancer Charity warn more research is needed before firm conclusions can be drawn...
HAVE YOUR SAY
to add a Comment.

By posting a comment you agree to abide by the BioNews terms and conditions


Syndicate this story - click here to enquire about using this story.